Abeona Therapeutics (ABEO)
(Delayed Data from NSDQ)
$4.98 USD
-0.12 (-2.35%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $4.98 0.00 (0.00%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ABEO 4.98 -0.12(-2.35%)
Will ABEO be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for ABEO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ABEO
Philips (PHG) Showcases New AI-Based Solutions at the RSNA
Philips (PHG) to Showcase New Innovations & Cardiac Solutions
ABEO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Philips (PHG) Expands Partnership to Build Angio CT Solution
Philips (PHG) Alerts Users of Health Hazards of Therapy Masks
Ultragenyx's (RARE) Q2 Earnings Miss Estimates, Revenues Up
Other News for ABEO
Insider Sale: Director Mark Alvino Sells Shares of Abeona Therapeutics Inc (ABEO)
Insider Sale: Director Christine Silverstein Sells Shares of Abeona Therapeutics Inc (ABEO)
Stifel Nicolaus Sticks to Their Buy Rating for Abeona Therapeutics (ABEO)
Abeona Therapeutics files for $300M securities offering
Abeona Therapeutics files $300M mixed securities shelf